QUOTED. July 6, 2018. Gerard Criner.
Executive Summary
Almost a decade after US FDA first rejected it, the agency approved Pulmonx Corp.'s Zephyr endobronchial valve system based on clinical results from the company's Liberate study and two other multicenter randomized control trials. See what Liberate lead investigator Gerard Criner said about the device here.
"Zephyr valves are a major step forward in treating severe emphysema patients who consistently feel short of breath despite all the medications we can offer." –Gerard Criner, chair and professor of thoracic medicine and surgery, Lewis Katz School of Medicine at Temple University
Click here for a free trial of Medtech Insight